Development of histone deacetylase inhibitors as therapeutics for neurological disease
- PMID: 20177429
- PMCID: PMC2824892
- DOI: 10.2217/fnl.09.55
Development of histone deacetylase inhibitors as therapeutics for neurological disease
Abstract
Postsynthetic modifications of histone and other chromosomal proteins by reversible acetylation and/or methylation regulate many aspects of chromatin dynamics, such as transcription, replication and DNA repair. Aberrant modification states are associated with several neurological and neuromotor diseases. Thus, small molecules that inhibit or activate the enzymes responsible for these chromatin modifications have received considerable attention as potential human therapeutics. This paper summarizes the current state of development of histone deacetylase inhibitors in a variety of neurological diseases.
References
Bibliography
-
- Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997;389:251–260. - PubMed
-
▪▪ Describes the structure of the nucleosome at atomic resolution and provides details for how nucleosomes might contribute to gene regulation.
-
- Hayes JJ, Hansen JC. Nucleosomes and the chromatin fiber. Curr Opin Genet Dev. 2001;11:124–129. - PubMed
-
- Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006;311:844–847. - PubMed
-
▪ Demonstrates that a particular histone modification can have a profound influence on chromatin structure and possibly gene expression.
-
- Jacobs SA, Khorasanizadeh S. Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail. Science. 2002;295:2080–2083. - PubMed
Website
-
- Clinical trials registry. www.clinicaltrials.gov.
Grants and funding
LinkOut - more resources
Full Text Sources